Session 91 - 12th CROI

Home

Session 91 Poster Abstracts
Vaccine Trials in Human Subjects
Friday, 1:30 - 3:30 pm
Hall A

501	Safety and Immunogenicity of a B-clade DNA Prime, Recombinant Fowl Pox Boost Regime: Results of a Phase I/IIa Trial Anthony Kelleher and Australian/Thai Vaccine Consortium Natl Ctr in HIV Epidemiology and Clin Res, Univ of New South Wales, Sydney, Australia
502	HIV-1 pGA2/JS2 Plasmid DNA Priming Vector Vaccine Is Safe and Well Tolerated in HIV-1-uninfected Adults M Mulligan¹, C Celum², M Allen³, J Kahn⁴, A Rubin², E Noonan², D Montefiori⁵, K Weinhold⁵, J Smith⁶, R Amara⁶, Harriet Robinson*⁶, and for the NIH/NIAID/DAIDS HIV Vaccine Trials Network ¹Univ of Alabama at Birmingham, USA; ²Fred Hutchinson Cancer Res Ctr, Seattle, WA, USA; ³NIAID, Bethesda, MD, USA; ⁴Univ of California, San Francisco, USA; ⁵Duke Univ Med Ctr, Durham, NC, USA; and ⁶Emory Univ, Atlanta, GA, USA
503	Safety Review of Merck’s Adenovirus Type-5 HIV Vaccines in Healthy Adults Michael Robertson*¹, J Kublin², R Leavitt¹, R Issacs¹, K Monahan¹, F Fan¹, R Mogg¹, and the V520 Study Groups ¹Merck Res Labs, West Point, PA, USA and ²Fred Hutchinson Cancer Res Ctr, Seattle, WA, USA
504	Safety and Immunogenicity of Adenovirus Type 5 (Ad5) HIV-1 gag Vaccines Clayton Harro*¹, S Edupuganti², P Goepfert³, F Priddy⁴, M Lally⁵, J Shiver⁶, X Li⁶, M Robertson⁶, R Leavitt⁶, R Isaacs⁶, and V520-007 and V520-012 Study Groups ¹Johns Hopkins Univ, Baltimore, MD, USA; ²Univ of North Carolina at Chapel Hill, USA; ³Univ of Alabama at Birmingham, USA; ⁴Emory Univ, Atlanta, GA, USA ; ⁵Miriam Hosp, Providence, RI, USA; and ⁶Merck Res Labs, West Point, PA, USA
505	Boosting Adenovirus Serotype 5 (Ad5) HIV-gag Primed Subjects with ALVAC HIV (vCP205) Paul Goepfert*¹, F Priddy², P Spearman³, C Harro⁴, S Edupuganti⁵, M Lally⁶, S Gurunathan⁷, L Bagylos⁷, C Meric⁷, J Tartaglia⁷, J Shiver⁸, D Mehrotra⁸, L Due⁸, M Robertson⁸, R Leavitt⁸, and V520-019 Study Group ¹Univ of Alabama at Birmingham, USA; ²Emory Univ, Atlanta, GA, USA ; ³Vanderbilt Univ, Nashville, TN, USA; ⁴Johns Hopkins Univ, Baltimore, MD, USA; ⁵Univ of North Carolina at Chapel Hill, USA; ⁶Brown Univ Sch of Med, Providence, RI, USA; ⁷Aventis Pasteur, Swiftwater, PA, USA; and ⁸Merck Res Labs, West Point, PA, USA
506	Detailed Characterization of the Cellular Immune Responses in Healthy Volunteers Immunized with Replication-defective Adenovirus HIV Vaccines Danilo Casimiro*, S Dubey, T Tobery, L Kierstead, J Condra, A Finnefrock, R Isaacs, M Robertson, R Leavitt, R Mogg, D Mehrotra, J Kublin, J Shiver, and V520 Merck Study Group Merck & Co, West Point, PA, USA
507	Analysis of the Safety and the Immunogenicity of a Pox Vector-based Vaccine Expressing Env, Gag, Pol, and Nef Proteins of HIV-1 Subtype C P -A Bart*¹, A Harari¹, M Khonkarly¹, G Tapia¹, E Medjitna-Rais¹, L Poupon¹, M J Frachette², S McCormack³, P Liljeström⁴, H Wolf⁵, G Pantaleo¹, and EUROVACC ¹Univ Hosp, Lausanne, Switzerland; ²Aventis Pasteur, Lyon, France; ³Med Res Council Clin Trials Unit, London, UK; ⁴Karolinska Inst, Stockholm, Sweden; and ⁵Univ of Regensburg, Germany
508	Induction of MVA-specific Antibodies and T cells in HIV-1-infected Patients and Healthy Controls by Immunization with a Recombinant MVA-nef Vector E Harrer¹, M Baeuerle¹, P Chaplin², B Petzold², A Handly², J Vollmar², J Hain², S Bergmann¹, K Eismann¹, and M Hamacher¹ ¹Univ Hosp Erlangen, Germany and ²Bavarian Nordic, Martinsried, Germany
509	Inguinal vs Deltoid Vaccination of vCP205 and Blood and Mucosal Immunity to HIV-1 F Javier Ibarrondo*, P Anton, M Fuerst, C Price, L Hultin, J Elliot, J Matud, H Ng, O Yang, and B Jamieson Geffen Sch of Med, Univ of California, Los Angeles, USA
510	CpG Adjuvant plus Hepatitis B Virus Vaccination in HIV Infection Achieves Sustained Seroprotection for as Long as 3 Years CL Cooper*¹, J Angel¹, I Seguin¹, J Clinch¹, H Davis², and D Cameron¹ ¹Univ of Ottawa at the Ottawa Hosp, Canada and ²Coley Pharma Group, Ottawa, Canada and Wellesley, MA, USA
511	Predictors of Successful Response to Hepatitis A Vaccine in HIV-infected Persons E Overton¹, Diana R Nurutdinova*¹, S Sungkanuparph¹, R Groger¹, W Seyfried¹, and W Powderly² ¹Washington Univ Sch of Med, St Louis, MO, USA and ²Univ Coll, Dublin, Ireland